Die Deutsche Pharmazeutische Gesellschaft, Landesgruppe Berlin-Brandenburg und das Institut für Pharmazie der Freien Universität Berlin laden ein zum 12. wissenschaftlichen Symposium unter dem Motto  „Der wissenschaftliche Nachwuchs stellt sich vor“.

Das Programm als PDF

Vorträge

09:00 – 09:05 Grußwort - Prof. Dr. Charlotte Kloft

Part 1 - Chair: Prof. Dr. Jörg Rademann
V1 09:05 – 09:20
M. Dubau, T. Tripetchr, B. Kleuser
Autologous approach to develop an immunocompetent skin model using iPSC-
generated fibroblast, keratinocytes, and immune cells

V2 09:20 – 09:35
Y. Jia, C. Arkona, Y. Pfeifer, L. Deng, B. Kuropka, C. Fröhlich, K. Ataka, S.
Bergemann, G. Wolber, H.-K. S. Leiros, M. Mielke, G. Werner, J. Rademann
Fragment-based development of inhibitors of New Delhi metallo- β-lactamase-1
(NDM-1) and validation of their mode-of-action against multiresistant bacteria

V3 09:35 – 09:50
F. Klima, A. Mc Laughlin, E. Schmulenson, O. Teplytska, S. Zimmermann, P.
Opitz, S. Groenland, A. Huitema, N. Steeghs, S. Fuxius, M. Joerger, F. Mayer, U.
Fuhr, S. Holdenrieder, G. Hempel, O. Scherf-Clavel, G. Mikus, U. Jaehde, C. Kloft
Feasibility of Therapeutic Drug Monitoring for targeted oral anticancer drugs in
clinical routine: The ON-TARGET study

V4 09:50 – 10:05
T. M. P. Neumann-Tran, D. Klinger
Turning the defense mechanism of antibiotic resistant bacteria against
themselves: New Polymer-Drug-Conjugates

10:05 – 10:10 Short break

Part 2 - Chair: Prof. Dr. Charlotte Kloft
V5 10:10 – 10:25
T. Noonan, D. Schaller, R. Nikolay, C. Spahn, M. Bermudez, G. Wolber
A novel antibiotic target: Identifying bacterial ribosomal assembly inhibitors via
3D pharmacophore-based virtual screening

V6 10:25 – 10:40
K. Pail, R. Bodmeier
Effect of glycerine on the conformation of Poloxamer P407 and its implication on
the nano-milling of a poorly water-soluble drug

V7 10:40 – 10:55
M. K. Parr, Y. Sun, L. Harps, M. Bureik
Human sulfotransferase assay with PAPS production in situ

10:55 – 11:00 Closing of Oral Presentation Sessions

11:00 – 12:30 Poster Präsentationen

Posters

• P1 M. N. Alam, A. Dashevskiy, R. Bodmeier
  Pulsatile drug release from compression-coated tablets
• P2 A. M. Ambros, P. Hailer, C. Arkona, G. Wolber, J. Rademann
  Molecular modeling and chemical optimization of fragment-based inhibitors of STAT5 as a novelbanti-leukemia strategy
• P3 L. B. S. Aulin, R. Michelet, M. Ursino, S. Boulet, J. C. Sirard, E. Comets, S. Zohar, C. Kloft
  The FAIR approach: Utilising a modelling and simulation workflow leveraging multisource data to support preclinical development and clinical trials
• P4 D. Bindellini, D. Busse, P. Simon, R. Michelet, D. Petroff, L. B. S. Aulin, C. Dorn, M. Zeitlinger, H. Wrigge, W. Huisinga, C. Kloft
  Semi-mechanistic model-based analysis to evaluate differences in plasma and target site cefazolin pharmacokinetics and protein binding in obese and nonobese patients
• P5 M. Breznik, S. Pach, S. Gobec, G. Wolber
  Retrosynthesis-driven in silico optimization of antiviral agents targeting 3C and 3C-like proteases
• P6 Y. Chen, Q. T. Wang
  The application oft he MM/GBSA method in the binding pose prediction of FGFR inhibitors
• P7 A. Démaris, E. L. Plan, W. Huisinga, L. B. S. Aulin, S. H. Lee, J. H. Lee, W. Reinisch, R. Michelet, C. Kloft
  Characterising and predicting the risk of immunogenicity in Crohn’s disease patients receiving infliximab therapy
• P8 P. Demirel, C. Arkona, J. Rademann
  Pre-biotic evolution of functional peptides through templated synthesis
• P9 K. Denzinger, M. Dündüz, G. Wolber
  Probing the binding pockets of L-type and T-type calcium channels using dynamic pharmacophores – a new approach for pain medication
• P10 Y. Dyck, D. Rehm, K. Winkler, V. Sandig, W. Jabs, M. K. Parr
  Identification of susceptible residues in a monoclonal antibody after forced degradation by peptide mapping
• P11 Y. Fan, M. K. Parr
  Complete reaction phenotyping of propranolol and 4-hydroxypropranolol with the 19 enzymes of the human UGT1 and UGT2 families
• P12 L. Gerlach
  Establishment of a method to determine the cell number of Schizosaccharomyces pombe for the standardisation of biotransformation assays
• P13 G. Giacomello, C. Boettcher, M. K. Parr
  Development and validation of a method to trace 13 C through glucose metabolism
• P14 T. Heinrich, A. Dashevskiy, R. Bodmeier
  Effect of ethanol on the release mechanism from hydrophilic matrix tablets
• P15 S. Kanwal, T. M. P. Neumann-Tran, D. Klinger
  New antimicrobial polymers to fight against resistant bacteria
• P16 F. Kias, R. Bodmeier
  Diafiltration-assisted solvent extraction for achieving rapid organic solvent removal during the preparation of biodegradable poly(lactide-co-glycolide) (PLGA) microparticles
• P17 D. Klemczak, A. Horatscheck, R. Raz, J. P. Kries, S. Bergemann, A. V. Rudnev, P. Broekmann, J. Rademann
  Peroxygenins (POG) are redox-activated inhibitors of protein tyrosine phosphatases and target cells with high reduction potential
• P18 A. P. Konrad, F. Bredendieck, F. Schumacher, C. Kloft
  Bioanalytical method development for the determination of target-site concentrations of posaconazole
• P19 L. Lassak, J. Rademann
  Pentafluorophosphato-phosphonates: biomimetics of organic pyrophosphates?
• P20 L. Y. Liu, L. Hobohm, F. Bredendieck, A. Froschauer, O. Zierau, M. K. Parr, A. M. Keiler
  Medaka embryos as a model for metabolism of anabolic steroids
• P21 S. Liu, F. Yang, M. K. Parr, G. Wolber
  Comparative modelling of human Uridine 5’-diphosphoglucuronosyltransferase guided by molecular dynamics (MD) simulations
• P22 C. López-Iglesias, R. Cui, A. Markovina, A. Gruber, D. Klinger
  Synthesis, characterization, and applications of amphiphilic nanogels based on polymethacrylates and polycarbonates
• P23 S. Märker, M. Körber, R. Bodmeier
  Mechanical properties of biodegradable poly(lactide-co-glycolide) (PLGA) implants determined by a three-point bending test
• P24 H. Mitdank, M. Tröger, A. Sonntag, N. A. Shirazi, E. Woith, H. Fuchs, D. Kobelt, W. Walther, A. Weng
  Suicide nanoplasmids coding for ribosome-inactivating proteins
• P25 F. L. Mueller, L. Ilia, K. Foerster, J. Burhenne, R. Michelet, C. Kloft
  Variability in protein binding determination: A comparison of microdialysis, ultrafiltration and rapid equilibrium dialysis
• P26 S. Pach, D. Schaller, G. Wolber
  Extracting 3D pharmacophores from molecular dynamics simulations: A case study
• P27 A. Prell, ,F. Schumacher, D. Wigger, B. Kleuser
  Target and off-target effects of sphingosine kinase inhibitors on the sphingolipidome in different cell lines
• P28 K. Puls, H. Schmidhammer, G. Wolber, M. Spetea
  Enlightment through dynamics: How the peripheral analgesic HS-731 discriminates between opioid receptors
• P29 A. Saoud, J. Rademann
  Pore-blockers: Small-molecule inhibitors of cholesterol-dependent cytolysins
• P30 L. Schlaak, C. Weise, B. Kuropka, A. Weng
  Sapovaccarin-S1 and -S2, two type I ribosome-inactivating protein isoforms from the seeds of Saponaria vaccaria L.
• P31 K. Schreck, M. F. Melzig
  The expression of selected intestinal glucose, fructose and long chain fatty acid transporters investigated in Caco-2 cells
• P32 W. Song, J. Rademann
  Development of orthosteric inhibitors of SHP2
• P33 A. Sonntag, H. Mitdank, A. Weng
  Construction of Minicircle suicide genes coding for ribosome-inactivating proteins
• P34 J. Steff, X. de la Torre, F. Botrè, M. K. Parr
  Stereoselective chemosynthetic approach to obtain metabolites of metandienone with a fully reduced A-ring as reference material
• P35 V. Talagayev, A. Dolsak, D. Sribar, G. Wolber, M. Sova, G. Weindl
  An innovative approach fo Toll-like receptor dynamics exploitation for structure optimization through 3D pharmacophore analysis
• P36 M. Tiemann, M. Accorsi, L. Wehrhan, L. M. Finn, R. Cruz, M. Rautenberg, F. Emmerling, J. Heberle, B. G. Keller, J. Rademann
  Pentafluorphosphato-phenyl-alanines as amphiphilic mimetics of phosphotyrosine
• P37 T. Tripetchr, M. Dubau, B. Kleuser
  Development of a skin sensitization assay using in vitro immunocompetent skin models
• P38 R. Wamser, S. Pach, C. Arkona, M. Baumgardt, U. B. A. Aziz, A. Hocke, G. Wolber, R. Rademann
  Covalent inhibitors of SARS-CoV-2 main protease targeting the S1-site with pyridine fragments
• P39 T. Wang, S. Staufenbiel, R. Bodmeier
  Preparation and characterization of a stabilizer-free dexamethasone oily nanosuspension
• P40 F. E. Weber, F. A. Weinelt, M. Stegemann, A. Theloe, F. Pfäfflin, L. Aulin, U. Trost,W. Huisinga, S. Hennig, C. Kloft
  Optimising meropenem dosing in the intensive care unit with a model-informed precision dosing tool: The TIAS study
• P41 E. Widigson, D. Busse, D. Bindellini, D. Petroff, C. Dorn, L. B. Aulin, R. Michelet, M. Zeitlinger, W. Huisinga, H. Wrigge, P. Simon, C. Kloft
  A pharmacometric evaluation of atypical plasma protein binding and probability of target attainment of tigecycline in obese and nonobese patients
• P42 E. Woith, A. Jendretzki, A. von zur Gathen, M. F. Melzig
  Plant extracellular vesicle lipids and secondary metabolites
• P43 C. A. Wolf, S. Liu, D. Machalz, J. Zhao, M. K. Parr, M. Bureik, G. Wolber
  Observing subtle changes in conformational dynamics caused by mutation P340A in orphan cytochrome P450 3A43 for drug design
• P44 W. Xie, M. F. Melzig
  The stability of medicinal plant microRNAs in herb preparation process
• P45 G. Ambrosio, T. Yuliandra, K. Touvleliou, B. Wuest, M. Mazzarino, X. de la Torre, F. Botrè, P. Diel, E. Isenmann, M. K. Parr
  Excretion study of ecdysterone following a single-dose administration in humans
• P46 C. Zhang, R. Bodmeier
  Encapsulating dexamethasone nanocrystals into PLGA microparticles by a simplified solvent evaporation process
• P47 X. Zhang, J. Rademann
  Development and evaluation of fragment-based inhibitors of SARS-CoV-2 main protease
• P48 N. Zimmermann, B. Pourshacheraghi, S. Wolf, T. Semmler, C. Kloft
  Integrated in vitro approach to understand the exposure-effect relationship of fosfomycin against Escherichia coli